Bibliography
- Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-357.
- Moutel S, Perez F. “Antibodies-Europe. Engineering the next generation of antibodies”. Biotechnol J 2008;3:298-300
- Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349-56
- Jefferis R. Glycosylation of Recombinant Antibody Therapeutics. Biotechnol Prog 2005;21:11-16
- Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007;7:1401-13
- Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007;12:898-910
- Sinclair AM, Elliott SJ. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. Pharm Sci 2005;94:626-1635
- Shields RL, et al. Lack of Fucose on Human IgG1 N-Linked oligosaccharide improves binding to human FcγRIII and Antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-40
- Shinkawa T, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73
- Niwa R, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005;306:151-60
- Ferrara C, et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 2006;93:851-61
- Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004;4:89-99
- Nezlin R, Ghetie V. Interactions of immunoglobulins outside the antigen-combining site. Adv Immunol 2004;82:155-215
- Krapp S, et al. Structural analysis of human IgG glycoforms reveals a correlation between oligosaccharide content, structural integrity and Fcγ-receptor affinity. J Mol Biol 2003;325:979-89
- Shields RL, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2002;276:6591-604
- Oganesyan V, et al. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 2008;45:1872-82